Original-Research: MPH Health Care AG (von First Berlin Equity Research GmbH): Kaufen
|
Original-Research: MPH Health Care AG - from First Berlin Equity Research GmbH
Classification of First Berlin Equity Research GmbH to MPH Health Care AG
First Berlin Equity Research hat ein Research Update zu MPH Health Care AG (ISIN: DE000A289V03) veröffentlicht. Analyst Ellis Acklin bestätigt seine BUY-Empfehlung und bestätigt sein Kursziel von EUR 37,00. Zusammenfassung: Wie erwartet wurde die Performance im ersten Halbjahr durch den starken Wertverlust der Beteiligung an CR Energy beeinträchtigt. CRE leitete im Juni ein vorläufiges Insolvenzverfahren ein, was zu einem Einbruch des Aktienkurses um 87% führte. Das Geschäft mit der anderen Kernbeteiligung, der M1 Kliniken AG, entwickelt sich hingegen weiterhin gut. Der Lifestyle- und Beauty-Spezialist verzeichnete für den Zeitraum Januar bis Juni erneut eine starke Performance mit einem Gewinnwachstum von über 20% gegenüber dem Vorjahr, dank eines starken Anstiegs der Margen im Beauty-Segment. Die Hauptversammlung hat kürzlich die Dividende von €1,20 für die MPH-Aktionäre genehmigt. Die Abschreibung von CRE war hart, aber die Aussichten für M1 sind ausgezeichnet. Das kürzlich gestraffte Klinikportfolio von M1 dürfte die Margen in Zukunft noch weiter steigern. Wir bekräftigen unsere Kaufempfehlung und unser Kursziel von €37 (Aufwärtspotenzial: 96%). First Berlin Equity Research has published a research update on MPH Health Care AG (ISIN: DE000A289V03). Analyst Ellis Acklin reiterated his BUY rating and maintained his EUR 37.00 price target. Abstract: As expected, six month performance was impacted by the sharp decline in the value of the CR Energy participation. CRE started preliminary insolvency proceedings in June triggering an 87% collapse in its share price. Meanwhile, business for the other core investment, M1 Kliniken AG, continues to be good. The lifestyle and beauty specialist booked another strong performance for the January to June period with earnings growth topping 20% YoY, thanks to a strong uptick in Beauty segment margins. The AGM recently approved the €1.2 dividend to MPH shareholders. The CRE write-down was hard, but the outlook for M1 is excellent. M1's recently streamlined clinic portfolio should boost margins even further going forward. We stick to our Buy rating and €37 target price (upside: 96%). Bezüglich der Pflichtangaben gem. §34b WpHG und des Haftungsausschlusses siehe die vollständige Analyse. You can download the research here: 93M1_GR-2025-09-18_EN Contact for questions: First Berlin Equity Research GmbH Herr Gaurav Tiwari Tel.: +49 (0)30 809 39 686 web: www.firstberlin.com E-Mail: g.tiwari@firstberlin.com
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
||||||||||||||||||||
2199908 18.09.2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Sales1 | 41,22 | 3,43 | 13,55 | 30,67 | 34,46 | 65,37 | 0,00 | |
| EBITDA1,2 | 11,59 | -70,99 | -9,05 | 29,59 | 29,54 | 32,99 | 0,00 | |
| EBITDA-Margin3 | 28,12 | -2.069,68 | -66,79 | 96,48 | 85,72 | 50,47 | 0,00 | |
| EBIT1,4 | 11,58 | -71,02 | -9,07 | 29,56 | 30,21 | 32,96 | 0,00 | |
| EBIT-Margin5 | 28,09 | -2.070,55 | -66,94 | 96,38 | 87,67 | 50,42 | 0,00 | |
| Net Profit (Loss)1 | 11,08 | -70,38 | -8,96 | 29,11 | 29,54 | 32,04 | 0,00 | |
| Net-Margin6 | 26,88 | -2.051,90 | -66,13 | 94,91 | 85,72 | 49,01 | 0,00 | |
| Cashflow1,7 | -1,35 | -2,89 | -1,09 | 0,01 | -2,02 | 1,83 | 0,00 | |
| Earnings per share8 | 2,60 | -16,44 | -2,09 | 6,80 | 6,90 | 7,48 | -6,90 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 1,20 | 1,20 | 1,20 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: wetreu NTRG
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| MPH Health Care | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A289V0 | DE000A289V03 | AG | 99,76 Mio € | 01.09.2009 | Kaufen | 9F4MCHV9+6R |
| PE 2026e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 11,65 | 4,89 | 2,38 | 5,35 | 0,37 | 54,54 | 1,53 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 1,20 | 1,20 | 1,20 | 5,02% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 17.07.2025 | 12.06.2025 | 16.09.2025 | 20.11.2025 | 28.05.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +25,88% | +14,98% | +5,75% | -1,24% | +0,00% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
